Table 1.

Summary of patient characteristics from the discovery cohort

Primary Invasive Cancers (n=95)
	Non-recurrent cases at the time of last follow-up 84 (88% of total)	Recurrent cases 11 (12%)	Significance tested using Chi-square analysis
Malignant Pathology			p=0.48
Invasive Ductal Carcinoma (IDC)	65 (77% of NR)	8 (73% of R)
Invasive Lobular Carcinoma (ILC)	8 (10%)	1 (7%)
IDC/ILC	9 (11%)	2 (14%)
Receptor Status			p= 0.37
Hormone Receptor Positive	61(73%)	9 (82%)
HER2 Positive	20 (24%)	2 (18%)
Triple Negative	11 (13%)	1 (9%)
Clinical Stage			p=0.02
Early Stage (1)	35 (41%)	1 (9%)
Advanced Stage (2-3)	45 (54%)	10 (91%)
DCIS			p=1
Present	67 (80%)	9 (82%)
Margins			p=0.07
Positive	40 (48%)	6 (55%)
Negative	40 (48%)	5 (45%)